Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

ABT-737

Catalog No: tcsc0014

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:
852808-04-9

Formula:
$C_{42}H_{45}ClN_6O_5S_2$

Pathway:
Autophagy;Apoptosis;Autophagy

Target:
Autophagy;Bcl-2 Family;Mitophagy

Purity / Grade:
>98%

Solubility:
DMSO : 50 mg/mL (61.47 mM; Need ultrasonic); H2O :

Observed Molecular Weight:
813.43

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

ABT-737 is a selective and BH3 mimetic **Bcl-xL**, **Bcl-2** and **Bcl-w** inhibitor with **EC_{50}**s of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

IC50 & Target: EC50: 78.7 nM (Bcl-xL), 30.3 nM (Bcl-2), 197.8 nM (Bcl-w)[3]

In Vitro: ABT-737 and ATO inhibits proliferation and induces apoptosis in SGC-7901 and MGC-803 cells in concentration- and time-dependent manner, and shows a synergistic effect. ABT-737 disturbs the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large[1]. ABT-737 induces a BAX/BAK-dependent impairment of maximal O_2 consumption rate in sensitive cells. Stable BCL-2 overexpression in MCF10A cells induces an ABT-737-sensitive primed for death state. ABT-737 induces dose-dependent impairment of maximal O_2 consumption rate in B-cell lymphoma cells[2]. ABT-737 induces apoptosis and synergizes with chemotherapy,and disrups BCL-2/BAX heterodimerization and induces BAX conformational change in AML cells[3].

In Vivo: ABT-737 (50 mg/kg, i.p.) and ATO significantly suppress SGC-7901 xenograft growth, synergistically inhibit tumour growth and induce apoptosis in vivo[1]. ABT-737 suppresses the leukemia burden by 48% and 53% at the 20 and 30 mg/kg dose levels, respectively[3].